EVAX Evaxion A/S

3.160USD+0.32%Mkt Cap: 28.51M $P/E: —

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanc…

Key Statistics

Company
Market Cap28.51M USD
Enterprise Value19.46M USD
Revenue (TTM)7.49M USD
Gross Profit7.49M USD
Net Income (TTM)-7.71M USD
Revenue/Share0.94 USD
Last Price3.160 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees46
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-210.67
PEG—
EV/EBITDA-2.34
EV/Revenue2.60
P/S3.81
P/B2.76
EPS (TTM)-1.00
EPS (Forward)-0.01
52W Range
2.7704% of range12.15
52W High12.15 USD
52W Low2.770 USD
Profitability
Gross Margin100.00%
Oper. Margin-116.02%
EBITDA Margin-111.15%
Profit Margin-102.38%
ROE-45.23%
ROA-27.13%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.63M USD
CapEx (TTM)11.00K USD
FCF Margin-73.26%
FCF Yield-19.25%
Net Debt-6.89M USD
Net Debt/EBITDA0.83
Balance Sheet
Debt/Equity0.44
Current Ratio5.06
Quick Ratio4.74
Book Value/Sh1.14 USD
Cash/Share1.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateJan 14, 2025
Analyst Consensus
Rating—
Target (Mean)11.25 USD
Upside (mean)+256.0%
Target Range9.000 USD – 16.00 USD
9.000+256.0% to mean16.00
# Analysts4
Ownership
Shares Out.9.02M
Float5.68M
Insiders16.15%
Institutions9.31%
Short Interest
Short Ratio0.1d
Short % Float0.71%
Short % Out.0.60%
Shares Short53.78K
Short (prev mo.)20.72K
Technical
SMA 503.123 (+1.2%)
SMA 2003.680 (-14.1%)
Beta0.51
S&P 52W Chg16.45%
Avg Vol (30d)398.25K
Avg Vol (10d)37.14K
Technical Indicators
RSI (14)48.2
MACD0.0148
MACD Signal0.0260
MACD Hist.-0.0112
BB Upper3.367 USD
BB Middle3.202 USD
BB Lower3.036 USD
BB Width10.32%
ATR (14)0.1544 USD
Vol Ratio (20d)0.83x